Compare BioNTech SE - ADR (BNTX) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Docusign Inc — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Docusign Inc trades at $58.19 (market cap $11.33B). The key difference: BioNTech SE - ADR is far larger — about 2.1× Docusign Inc's market cap, and Docusign Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | DOCU | |
|---|---|---|
Market Cap | $23.31B | $11.33B |
Sector | Health | Technology |
52-Week High | $119.34 | $85.01 |
52-Week Low | $83.89 | $41.75 |
Enterprise Value | $6.60B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DOCU trades at $59.64, down 1.03% today but maintaining strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $2.8B in 2024 to $3.0B in 2025 and impressive net income margin expansion to 35.87%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.09 surpassing the $0.994 estimate. Institutional activity shows mixed signals with some funds reducing positions while others increase exposure.
DOCU presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation remains elevated at 38.53 P/E. The stock faces near-term resistance at $60-$62 levels with overbought RSI conditions. Analyst consensus leans cautious with 67.86% hold ratings, suggesting potential consolidation before further upside. Key risks include competitive pressures in e-signature space and execution challenges in maintaining current growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
